禮來(LLY)升逾1% 替爾泊肽正式在中國上市

金吾財訊

2025/01/02

金吾財訊 | 禮來(LLY)升逾1%，截至發稿，報782.33美元。消息面上，從禮來(LLY)中國獲悉，葡萄糖依賴性促胰島素多肽(GIP)/ 胰高糖素樣肽-1(GLP-1)受體激動劑替爾泊肽(商品名：穆峯達)正式在中國上市，同時覆蓋兩項適應證，包括二型糖尿病和減重。穆峯達目前在中國上市了4種規格，包括2.5 mg:0.5ml，5 mg:0.5ml，7.5 mg:0.5ml，10 mg:0.5ml。穆峯達是全球首個且目前唯一獲批用於二型糖尿病和長期體重管理的每周一次GIP/ GLP-1受體激動劑。減重版替爾泊肽在2024年前三季度收入30.18億美元，與諾和諾德GLP-1藥物司美格魯肽在全球GLP-1賽道的第一梯隊。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2500975340"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2500975340\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2500975340?lang=zh_TW&edition=fundamental","thumbnail":"https://static.szfiu.com/news/20210625/NWUyOTcwN2U1MzQ2YjViNjMyZDcwZGM2MmQ0YzE5MjMxNzMwNDc5NDg=.jpg","is_english":false,"pubTime":"2025-01-02 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500975340","market":"nz","top_or_hot":-1,"title":"禮來(LLY)升逾1% 替爾泊肽正式在中國上市","media":"金吾財訊","content":"<html><body><p>金吾財訊 | <a href=\"https://laohu8.com/S/LLY\">禮來</a>(LLY)升逾1%，截至發稿，報782.33美元。消息面上，從禮來(LLY)中國獲悉，葡萄糖依賴性促胰島素多肽(GIP)/ 胰高糖素樣肽-1(GLP-1)受體激動劑替爾泊肽(商品名：穆峯達)正式在中國上市，同時覆蓋兩項適應證，包括二型糖尿病和減重。穆峯達目前在中國上市了4種規格，包括2.5 mg:0.5ml，5 mg:0.5ml，7.5 mg:0.5ml，10 mg:0.5ml。穆峯達是全球首個且目前唯一 獲批用於二型糖尿病和長期體重管理的每周一次GIP/ GLP-1受體激動劑。減重版替爾泊肽在2024年前三季度收入30.18億美元，與<a href=\"https://laohu8.com/S/NVO\">諾和諾德</a>GLP-1藥物司美格魯肽在全球GLP-1賽道的第一梯隊。</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>禮來(LLY)升逾1% 替爾泊肽正式在中國上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n禮來(LLY)升逾1% 替爾泊肽正式在中國上市\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086022552\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">金吾財訊 </p>\n<p class=\"h-time smaller\">2025-01-02 23:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p>金吾財訊 | <a href=\"https://laohu8.com/S/LLY\">禮來</a>(LLY)升逾1%，截至發稿，報782.33美元。消息面上，從禮來(LLY)中國獲悉，葡萄糖依賴性促胰島素多肽(GIP)/ 胰高糖素樣肽-1(GLP-1)受體激動劑替爾泊肽(商品名：穆峯達)正式在中國上市，同時覆蓋兩項適應證，包括二型糖尿病和減重。穆峯達目前在中國上市了4種規格，包括2.5 mg:0.5ml，5 mg:0.5ml，7.5 mg:0.5ml，10 mg:0.5ml。穆峯達是全球首個且目前唯一 獲批用於二型糖尿病和長期體重管理的每周一次GIP/ GLP-1受體激動劑。減重版替爾泊肽在2024年前三季度收入30.18億美元，與<a href=\"https://laohu8.com/S/NVO\">諾和諾德</a>GLP-1藥物司美格魯肽在全球GLP-1賽道的第一梯隊。</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014898.SGD","symbol_name":"United Global Quality Growth Fund Dis SGD","start_time":0,"source_url":"283920","article_id":"2500975340","we_media_id":"1086022552","thumbnails":["https://static.szfiu.com/news/20210625/NWUyOTcwN2U1MzQ2YjViNjMyZDcwZGM2MmQ0YzE5MjMxNzMwNDc5NDg=.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500975340","pubTimestamp":1735831690,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"金吾財訊","introduction":"「金吾财讯」以精准用户需求为切入点，打造一站式港美股投资细分领域品牌。依托战略合作伙伴凤凰网财经，将港美股内容传播到全球华人圈。","home_visible":1,"id":"1086022552","head_image":"https://static.tigerbbs.com/19a93586c3b023ec6ebfed568990555c"},"summary":"金吾財訊 | 禮來 升逾1%，截至發稿，報782.33美元。消息面上，從禮來中國獲悉，葡萄糖依賴性促胰島素多肽/ 胰高糖素樣肽-1受體激動劑替爾泊肽正式在中國上市，同時覆蓋兩項適應證，包括二型糖尿病和減重。穆峯達是全球首個且目前唯一 獲批用於二型糖尿病和長期體重管理的每周一次GIP/ GLP-1受體激動劑。減重版替爾泊肽在2024年前三季度收入30.18億美元，與諾和諾德GLP-1藥物司美格魯肽在全球GLP-1賽道的第一梯隊。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0238689110.USD":"贝莱德环球动力股票基金","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","BK4585":"ETF&股票定投概念","LLY":"礼来","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU2461242641.AUD":"WELLINGTON US QUALITY GROWTH \"A\" (AUDHDG) ACC","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","BK4516":"特朗普概念","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD"},"translate_title":"Eli Lilly (LLY) rose more than 1%, telpotide officially launched in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"金吾財訊 | 禮來(LLY)升逾1%，截至發稿，報782.33美元。消息面上，從禮來(LLY)中國獲悉，葡萄糖依賴性促胰島素多肽(GIP)/ 胰高糖素樣肽-1(GLP-1)受體激動劑替爾泊肽(商品名：穆峯達)正式在中國上市，同時覆蓋兩項適應證，包括二型糖尿病和減重。穆峯達目前在中國上市了4種規格，包括2.5 mg:0.5ml，5 mg:0.5ml，7.5 mg:0.5ml，10 mg:0.5ml。穆峯達是全球首個且目前唯一 獲批用於二型糖尿病和長期體重管理的每周一次GIP/ GLP-1受體激動劑。減重版替爾泊肽在2024年前三季度收入30.18億美元，與諾和諾德GLP-1藥物司美格魯肽在全球GLP-1賽道的第一梯隊。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}